Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atrys HealthXMAD:ATRY -0.20%58 Days Sales Outstanding is 118.97 as of Dec. 2025, which is 16% below its 10-year median of 141.06. GuruFocus rates XMAD:ATRY with a GF Score™ of 58/100 and a GF Value™ of €3.24 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 839 Biotechnology companies, Atrys Health ranks worse than 66.39% on this metric.
Atrys Health's average Accounts Receivable for the
six
months ended in Dec. 2025 was €45.6 Mil. Atrys Health's Revenue for the
six
months ended in Dec. 2025 was €69.9 Mil.
Hence, Atrys Health's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 118.97.
The historical rank and industry rank for Atrys Health's Days Sales Outstanding or its related term are showing as below:
XMAD:ATRY'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 90.81 Med: 141.06 Max: 217.83
Current: 93.39
During the past 10 years, Atrys Health's highest Days Sales Outstanding was 217.83. The lowest was 90.81. And the median was 141.06.
XMAD:ATRY's Days Sales Outstanding is ranked worse than 66.39% of 839
companies
in the Biotechnology industry
Industry Median: 68.64
vs XMAD:ATRY: 93.39
Atrys Health's Days Sales Outstanding
declined
from Dec. 2024 (150.50) to Dec. 2025 (118.97).
Atrys Health (XMAD:ATRY) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Atrys Health Days Sales Outstanding Related Terms
Atrys Health Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Atrys Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Atrys Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Atrys Health's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 118.97 mean?
Atrys Health (XMAD:ATRY) has a Days Sales Outstanding of 118.97 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Atrys Health and its competitors. This is 16% below median its historical median of 141.06. Over the past decade, Atrys Health's Days Sales Outstanding has ranged from 90.81 to 217.83. According to the industry distribution chart, Atrys Health ranks #557 out of 839 companies in the Biotechnology industry, placing it in the top 66.4%.
Is Atrys Health's Days Sales Outstanding too high?
Atrys Health's current Days Sales Outstanding of 118.97 is 16% below median its 10-year median of 141.06. Over the past 10 years, this metric has ranged from a low of 90.81 to a high of 217.83. The Biotechnology industry median Days Sales Outstanding is 68.64. Atrys Health's value of 118.97 is 73.3% above this industry median. Based on the distribution chart, Atrys Health ranks #557 out of 839 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atrys Health has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #557 out of 839 companies for Days Sales Outstanding. This places Atrys Health in the lower half of its industry. The industry median Days Sales Outstanding is 68.64. Atrys Health's value of 118.97 is 73.3% above this benchmark. Historically, Atrys Health's own Days Sales Outstanding has ranged from 90.81 to 217.83 over the past decade. While the company's 10-year median is 141.06 vs. the industry median of 68.64, Atrys Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.64, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrys Health's current Days Sales Outstanding of 118.97 is 73.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Atrys Health and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrys Health's current Days Sales Outstanding is 118.97, which is 16% below median its own 10-year median of 141.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.24, compared to a current price of €2.56 — trading 21.1% below its estimated fair value. The current Days Sales Outstanding is 118.97, which is 16% below median its 10-year median of 141.06 and 73.3% above the Biotechnology industry median of 68.64. Atrys Health's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Days Sales Outstanding is 118.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.56 is trading 21.1% below its estimated GF Value™ of €3.24.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
Days Sales Outstanding: 118.97 (16% below median its 10-year median of 141.06)
GF Value™: €3.24 vs. price of €2.56 (21.1% below fair value)
Industry Position: 73.3% above the Biotechnology median (#557 of 839)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
58GF Score
Get the complete analysis for XMAD:ATRY
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
